Orano Med
Orano Med is the leading lead-212 producer and the developer of 212Pb-DOTAMTATE (AlphaMedix).
Overview
Orano Med, based in Paris and Plano, Texas, is the leading producer of lead-212 and the developer of 212Pb-DOTAMTATE, known as AlphaMedix, an alpha-emitting radioligand for somatostatin-receptor-positive neuroendocrine tumours. AlphaMedix reported a 56 percent objective response rate in its phase 2, the company builds lead-212 generators, and it works with Sanofi and RadioMedix. Nuclide links it to neuroendocrine tumours, to somatostatin receptor 2 as a target, to peptide receptor radionuclide therapy, targeted alpha therapy and the isotope supply chain, and to the idea of funding alpha emitters beyond actinium-225, including lead-212, terbium-149 and astatine-211. Manufacturing cost and time for radioactive medicines is the bottleneck it sits inside. Whether lead-212 can be delivered to enough hospitals to matter is the open question.
Scorecard
All companies- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +2
Deals
Deal mapManufacturing
Capacity map- Orano Med Plano Plano, Texas, USRadioisotope production, Radiopharmaceutical manufacturing
An alpha-particle version of neuroendocrine radioligand therapy that produced responses in over half of patients who had never had PRRT, with FDA Breakthrough designation.
Similar pages
not linked directly; found by shared links- CompanyTerraPower Isotopes
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Actinium-225 supply, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline.
- AgentActinium-225 DOTATATE
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Actinium-225 supply, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Radiopharmaceutical roadmap: iodine → lutetium → actinium.
- CompanyRayzeBio (BMS)
Shares Actinium-225 supply, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Actinium-225 supply: thorium stocks, accelerators and radium targets.
- CompanyITM Isotope Technologies Munich
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Manufacturing cost and time for living and radioactive medicines, Actinium-225 supply: thorium stocks, accelerators and radium targets, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- TrialALPHAMEDIX-02
Shares 212Pb-DOTAMTATE, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Lead-212, Peptide receptor radionuclide therapy (PRRT).
- CompanyNorthStar Medical Radioisotopes
Shares Actinium-225 supply, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Actinium-225 supply: thorium stocks, accelerators and radium targets, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- AgentActinium-225 PSMA agents
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Actinium-225 supply, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Radiopharmaceutical roadmap: iodine → lutetium → actinium.
- IdeaA global medical isotope supply observatory with forecasts and shortage alerts
Shares Actinium-225 supply, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Targeted alpha therapy.